



E·N·C·O·R·E

ENCORE: A Study to Investigate the Durability of Polymer EVAR

A Contemporary Review of 1,296 Patients




ENCORE includes results from a real-world patient population. 3% of patients had neck characteristics beyond the FDA-approved anatomic IFU. Safety and effectiveness of Ovation when used outside the IFU have not been established. ©2021 Endologix LLC. All rights reserved. MM1918 Rev 03.

Agenda

01 ENCORE Results: Demonstrated favorable midterm durability* at 5 years

02 ENCORE: 5-year wide neck analysis





E·N·C·O·R·E

Effective**N**ess of **C**ustom Seal with **O**vation: **R**evision of the **E**vidence

The Ovation platform product family includes a series of device iterations using adaptive neck sealing technology such as Ovation, Ovation Prime, Ovation iX, and Alto. The devices included in the studies used in the ENCORE Analysis all include adaptive sealing technology.

5-Year Results from JVS Publication

ENCORE demonstrates favorable midterm durability at 5 years evidenced by successful aneurysm exclusion and low aneurysm-related mortality.

Journal of Vascular Surgery 2019

ARTICLE IN PRESS

Five-year results of endovascular abdominal aortic aneurysm repair with the Ovation abdominal stent graft

Nicholas J. Swerdlow, MD,^a Sean P. Lyden, MD,^b Hence J. M. Verhagen, MD,^c and Marc L. Schermerhorn, MD,^a
Boston, Mass; Cleveland, Ohio; and Rotterdam, The Netherlands

ABSTRACT

Objective: Endovascular abdominal aortic aneurysm repair (EVAR) has been rigorously compared with open repair for the treatment of abdominal aortic aneurysms in randomized trials and observational studies, but a comparison of individual devices is lacking, and single-device registries and trials are limited by small sample size. Here we report a descriptive analysis of the Effectiveness of Custom Seal with Ovation: Review of the Evidence (ENCORE) database, pooled results of multiple studies evaluating the midterm results of EVAR with the Ovation Abdominal Stent Graft Platform.

Methods: This is a retrospective analysis of the ENCORE database, a cohort of patients undergoing EVAR with the Ovation platform composed of pooled, prospectively collected data from 1296 patients from five clinical trials and the prospectively maintained European Union Post-Market Registry. The primary outcomes were 5-year rates of type IA and type I or III endoleak. Secondary outcomes included were 30-day mortality, 30-day major adverse event, technical success (successful deployment of the aortic body and iliac limbs), as well as 5-year survival, and freedom from aneurysm-related mortality, type II endoleak, device-related intervention, aneurysm rupture, sac expansion, and conversion to open repair.

Results: A total of 1296 patients were included in the analysis. The average age was 73 ± 8 years and 81% of patients were male. Fifty percent of patients had complex aortic anatomy, (neck length <10 mm, neck diameter >28 mm, neck angle $>60^\circ$, reverse neck taper $>10\%$, distal common iliac artery diameter <10 mm, or external iliac artery diameter <6 mm). Technical success was 99.7%. Thirty-day mortality was 0.3%, 30-day rate of major adverse event was 1.6%, and polymer leak rate was 0.2%. Freedom from type IA endoleak at 1, 3, and 5 years was 97.6%, 97.1%, and 95.8%, respectively; type I or III endoleak at 1, 3, and 5 years was 96.9%, 95.7%, and 94.0%, respectively. Freedom from device-related reintervention at 1, 3, and 5 years was 96.2%, 94.4%, and 92.4% and primary freedom from sac expansion was 97.0% at 1 year, 90.3% at 3 years, and 84.9% at 5 years. Freedom from all-cause mortality and aneurysm-related mortality at 5 years were 78.9% and 99.3%, respectively.

Conclusions: This analysis of the ENCORE database demonstrates that EVAR with the Ovation platform has favorable midterm durability evidenced by successful aneurysm exclusion and 5-year freedom from aneurysm-related mortality. (J Vasc Surg 2019; ■:1-10.)

Keywords: Abdominal aortic aneurysms; EVAR; Endoleak


Patient Demographics

Demographic	ENCORE Cohort
Age (yrs)	73 ± 8
Female sex	19 %
Body mass index (kg/m ²)	28 ± 5
Hypertension	18 %
Congestive heart failure	6.0 %
COPD	33 %
Diabetes	22 %
History of myocardial infarction	21 %
History of stroke	9.3 %
Family history	12 %
Smoking history	71 %

Characteristic	ENCORE Cohort
Maximum AAA diameter (mm)	54 ± 9
<50 mm	27 %
≥50 mm and <60 mm	55 %
≥60 mm and <70 mm	13 %
≥70 mm	6.0%
Neck diameter (IR, mm)	22 ± 3
>28 mm	4.4 %
Neck diameter (IR + 13, mm)	23 ± 3
Neck reverse taper ≥10%	28 %
Distal CIA (mm)	14 ± 4
<10 mm	11 %
Minimum EIA (mm)	8 ± 2
<6 mm	14 %
Aortic neck angulation	19 ± 19
Complex anatomy*	53%

*Complex anatomy (neck length < 10, or neck diameter >28, or taper >10%, or neck angle >60, or sac diameter >70mm, or distal common iliac diameter <10mm, or external iliac diameter <6mm). Result excludes subjects who had missing info from any of these variables.

Acute Procedural Outcomes



Procedure time (min) ¹	94
Fluoroscopy time (min) ¹	19
Contrast volume (mL) ¹	105
General Anesthesia (%) ²	55
Technical Success (%) ²	99.7
MAE (%) ²	1.6
30d Mortality (%) ²	0.3
Polymer Leak (%) ³	0.9


1. ENCORE Data Cut March 20, 2019.

2. Swerdlow et al. J Vasc Surg. 2020; 71: 1528-1537

3. May 4, 2020, Ovation iX Medical Device Correction <https://endologix.com/wp-content/uploads/2020/05/ENDO-Ovation-FSN-FS-0012-US-Letter-Final-5-6-20.pdf>. (Assessed Feb 3, 2021)


ENCORE includes results from a real-world patient population. 3% of patients had neck characteristics beyond the FDA-approved anatomic IFU. Safety and effectiveness of Ovation when used outside the IFU have not been established. ©2021 Endologix LLC. All rights reserved. MM1918 Rev 03.

Freedom from AAA-Related Mortality



	Year 1	Year 3	Year 5
FF ARM (%)	99.6	99.5	99.3

Freedom from Type IA Endoleak



	Year 1	Year 3	Year 5
FF Type IA EL (%)	97.6	97.0	95.7


Outcomes

ENCORE Freedom From (%) ¹	Year 1	Year 3	Year 5
AAA-Related Mortality	99.6	99.5	99.3
Type IA Endoleak	97.6	97.0	95.7
Sac Expansion ²	97.0	90.3	84.9
Rupture	99.8	99.8	99.5
Conversion	99.9	99.5	98.6
Device-Related Reintervention	95.9	93.8	90.2

1. All values come from ENCORE Data Cut: March 20, 2019 except for sac expansion which comes from ENCORE Data Cut: April 12, 2018.

2. ENCORE data cut: April 12, 2018

ENCORE includes results from a real-world patient population. 3% of patients had neck characteristics beyond the FDA-approved anatomic IFU. Safety and effectiveness of Ovation when used outside the IFU have not been established. ©2021 Endologix LLC. All rights reserved. MM1918 Rev 03.



E·N·C·O·R·E

POLYMER EVAR-OVATION®

Modern, Systematic Evidence Base of 1,296 patients

Pooled, retrospective analysis of six trials demonstrate favorable midterm durability at five-years

- 99.3% FF AAA-Related Mortality
- 95.7% FF Type IA Endoleak
- 99.5% FF Rupture
- 98.6% FF Conversion
- 90.2% FF Device-Related Reintervention

The ENCORE analysis pools data using a March 20, 2019 data cut.

Agenda

01 ENCORE Results: Demonstrated favorable midterm durability* at 5 years

02 ENCORE: 5-year wide neck analysis



EVAR durability: developing information on wide aortic necks

From the Society for Vascular Surgery

Outcomes of endovascular aneurysm repair performed in abdominal aortic aneurysms with large infrarenal necks



Mauro Gargiulo, MD, PhD,^a Enrico Gallitto, MD, PhD,^a Helene Watzek, MD,^b Fabio Verzini, MD, PhD,^c Claudio Bianchini Massoni, MD,^a Diletta Loschi, MD,^c Antonio Freyrie, MD, PhD,^a and Stephan Haulon, MD, PhD,^d Bologna and Perugia, Italy; and Lille, France

ABSTRACT

Objective: The aim of this study was to evaluate midterm clinical and morphologic outcomes after endovascular aneurysm repair (EVAR) of abdominal aortic aneurysm (AAA) with large (≥ 28 mm) infrarenal neck.

Methods: From 2009 to 2012, we prospectively collected and retrospectively analyzed clinical, morphologic, and intraoperative and postoperative data of patients undergoing EVAR for wide-neck AAA at three European vascular surgery units. All patients had computed tomography angiography follow-up of ≥ 24 months. The early end points were technical success and proximal type I endoleak at 30 days. The midterm end points were type Ia endoleak, freedom from reintervention (FFR), survival, AAA-related mortality, and infrarenal and suprarenal aortic diameter progression. The aortic diameters were measured on three-dimensional workstation center lumen line reconstructions, 1 cm below the lowest renal artery, at the level of the renal arteries, at the superior mesenteric artery, and at the celiac trunk. Preoperative and 24-month aortic diameters were compared by paired t-test. Survival and FFR were evaluated by Kaplan-Meier analysis.

Results: During the study period, 118 patients (74 \pm 8 years) were enrolled. The mean aneurysm diameter was 61 ± 10 mm. Suprarenal and infrarenal fixation endografts were implanted in 102 (86%) and 16 (14%) patients, respectively. The mean main body oversizing was $17\% \pm 9\%$. Technical success rate was 98% (three type Ia endoleaks at 30 days). The mean follow-up was 38 ± 12 months. Fourteen type Ia endoleaks (12%) were detected during follow-up. Survival at 3 years and 5 years was 89% and 70%, respectively. Four deaths (3.4%) were type Ia endoleak related. FFR at 1 year, 3 years, and 5 years was 96%, 83%, and 82%, respectively. Eight reinterventions (7%) were proximal neck related. All infrarenal and suprarenal aortic diameters increased at 24 months. The mean increase was 1% for the lowest renal artery (29.1 ± 1.1 mm preoperatively vs 32.3 ± 4.5 mm at 24 months; $P < .001$), 3% to 5% at the level of the renal arteries, and $< 3\%$ for the superior mesenteric artery and the celiac trunk. Neck length < 15 mm ($P = .032$), stainless steel endograft ($P = .003$), and type Ia endoleak at 24 months ($P = .001$) were associated with infrarenal neck enlargement on multivariate logistic regression.

Conclusions: EVAR performed in AAAs with large necks is associated with a significant infrarenal aortic neck enlargement at 24 months as well as with a high risk of proximal type I endoleak and proximal neck-related reinterventions. In this subgroup of patients, main body oversizing $> 15\%$ and suprarenal sealing should be considered. (J Vasc Surg 2017;66:1065-72.)

- > 28 mm neck
- 38 month mean follow up
- 12% Type IA endoleak, 3.4% endoleak related death
- 7% proximal neck reintervention

From the Society for Vascular Surgery

Infrarenal endovascular aneurysm repair with large device (34- to 36-mm) diameters is associated with higher risk of proximal fixation failure



Graeme McFarland, MD, Kenneth Tran, BS, Whitt Virgin-Downey, BS, Michael D. Sgroi, MD, Venita Chandra, MD, Matthew W. Mell, MD, E. John Harris, MD, Ronald L. Dalman, MD, and Jason T. Lee, MD, Stanford, Calif

ABSTRACT

Objective: Endovascular aneurysm repair (EVAR) has become the standard of care for infrarenal aneurysms. Endografts are commercially available in proximal diameters up to 36 mm, allowing proximal seal in necks up to 32 mm. We sought to further investigate clinical outcomes after standard EVAR in patients requiring large main body devices.

Methods: We performed a retrospective review of a prospectively maintained database for all patients undergoing elective EVAR for infrarenal abdominal aortic aneurysms at a single institution from 2000 to 2016. Only endografts with the option of a 34- to 36-mm proximal diameter were included. Requisite patient demographics, anatomic and device-related variables, and relevant clinical outcomes and imaging were reviewed. The primary outcome in this study was proximal fixation failure, which was a composite of type Ia endoleak and stent graft migration > 10 mm after EVAR. Outcomes were stratified by device diameter for the large-diameter device cohort (34-36 mm) and the normal-diameter device cohort (< 34 mm).

Results: There were 500 patients treated with EVAR who met the inclusion criteria. A total of 108 (21.6%) patients received large-diameter devices. There was no difference between the large-diameter cohort and the normal-diameter cohort in terms of 30-day (0.9% vs 0.9%; $P = .960$) or 1-year mortality (9.0% vs 6.2%; $P = .920$). Proximal fixation failure occurred in 24 of 392 (6.1%) patients in the normal-diameter cohort and 26 of 108 (24%) patients in the large-diameter cohort ($P < .001$). There were 15 (5.3%) type Ia endoleaks in the normal-diameter cohort and 16 (14.8%) in the large-diameter cohort ($P < .001$). Stent graft migration (> 10 mm) occurred in 15 (3.8%) in the normal-diameter cohort and 16 (14.8%) in the large-diameter cohort ($P < .001$). After multivariate analysis, only the use of Talent (Medtronic, Minneapolis, Minn) endografts (odds ratio [OR], 4.50; 95% confidence interval [CI], 1.18-17.21) and neck diameter ≥ 29 mm (OR, 2.50; 95% CI, 1.12-5.08) remained significant independent risk factors for development of proximal fixation failure (OR, 3.99; 95% CI, 1.75-9.11).



Conclusions: Standard EVAR in patients with large infrarenal necks ≥ 29 mm requiring a 34- to 36-mm diameter endograft is independently associated with an increased rate of proximal fixation failure. This group of patients should be considered for more proximal seal strategies with fenestrated or branched devices vs open repair. Also, this group likely needs more stringent radiographic follow-up. (J Vasc Surg 2019;63:385-393.)

Keywords: Aortic aneurysm; EVAR; Endovascular aneurysm repair; Endoleak; Stent migration; Aortic neck; Infrarenal aneurysm; Neck diameter

- > 34 mm vs < 34 mm devices
- Proximal fixation failure 6.1% vs 24%
- Type IA endoleak 3.3% vs 14.8%
- Migration 3.8% vs 14.8%


Wide neck analysis – why now?

- Validation that aortic neck dilation is common after EVAR
- Associated with wide proximal neck and degree of oversizing
- Suggestion that the use of endoanchors reduces aortic neck dilatation and increases sac regression
- Contention that fenestrated grafts increase the length of seal zone and are opposed to healthy aorta resistant to dilation



Tassipoulos et al JVS 2017; 66: 45
Muhs et al JVS 2018; 67: 1699

ENCORE includes results from a real-world patient population. 3% of patients had neck characteristics beyond the FDA-approved anatomic IFU. Safety and effectiveness of Ovation when used outside the IFU have not been established. ©2021 Endologix LLC. All rights reserved. MM1918 Rev 03.




E·N·C·O·R·E

Effective**N**ess of **C**ustom Seal with **O**vation: **R**evision of the **E**vidence

The Ovation platform product family includes a series of device iterations using adaptive neck sealing technology such as Ovation, Ovation Prime, Ovation iX, and Alto. The devices included in the studies used in the ENCORE Analysis all include adaptive sealing technology.


Freedom from AAA-Related Mortality



Durability remains consistent regardless of size

Device Diameter (mm)	5 years
34	98.9%
20, 23, 26, 29	99.4%


Freedom from Rupture



Durability remains consistent regardless of size

Device Diameter (mm)	5 years
34	98.9%
20, 23, 26, 29	99.6%


Freedom from Conversion



Durability remains consistent regardless of size

Device Diameter (mm)	5 years
34	98.2%
20, 23, 26, 29	98.6%


Freedom from Type IA Endoleak



No degradation of performance over time

Device Diameter (mm)	5 years
34	94.2%
20, 23, 26, 29	96.1%

Freedom from Device-Related Reintervention



Durability remains consistent regardless of size

Device Diameter (mm)	5 years
34	88.7%
20, 23, 26, 29	90.6%



INDICATIONS FOR USE: The ALTO® Abdominal Stent Graft System is indicated for treatment of patients with infrarenal abdominal aortic aneurysms having the vascular morphology suitable for endovascular repair with the device, which includes the following:

- Adequate iliac/femoral access compatible with vascular access techniques (femoral cutdown or percutaneous), devices, and/or accessories,
- A proximal aortic landing zone for the sealing ring 7 mm below the inferior renal artery.
- An aortic sealing zone comprised of healthy aorta defined as:
 - Lack of significant thrombus > 8 mm in thickness; at any point along the aortic circumference at the level of 7mm below the inferior renal artery,
 - Lack of significant calcification at the level of 7 mm below the inferior renal artery,
 - Conicity < 10% as measured from the inferior renal artery to the aorta 7 mm below the inferior renal artery,
 - An inner wall diameter of no less than 16 mm and no greater than 30 mm at 7 mm below the inferior renal artery, and
 - An aortic angle of ≤ 60 degrees
- A distal iliac landing zone:
 - With a length of at least 10 mm, and
 - With an inner wall diameter of no less than 8 mm and no greater than 25 mm.

CONTRAINDICATIONS: The system is contraindicated for use in patients who have a condition that threatens to infect the graft and in patients with known sensitivities or allergies to the device materials including polytetrafluoroethylene [PTFE], polyethylene glycol [PEG]-based polymers, contrast agents, fluorinated ethylene propylene [FEP], titanium, nickel, platinum, or iridium.

Refer to Instructions for Use for more information concerning Indications, Contraindications, Specific Anatomic Considerations, Warnings, Precautions, and Adverse Events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

NOTE: Not all product components are available in every country. Please consult with your Endologix representative to confirm product availability.

©2021 Endologix LLC. All rights reserved. MM1918 Rev 03